Literature DB >> 21184112

Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia.

Mitchell Roslin1, Tanuja Damani, Jonathan Oren, Robert Andrews, Edward Yatco, Paresh Shah.   

Abstract

BACKGROUND: Symptoms of reactive hypoglycemia have been reported by patients after Roux-en-Y gastric bypass (RYGB) surgery who experience maladaptive eating behavior and weight regain. A 4-h glucose tolerance test (GTT) was used to assess the incidence and extent of hypoglycemia.
METHODS: Thirty-six patients who were at least 6 months postoperative from RYGB were administered a 4-h GTT with measurement of insulin levels. Mean age was 49.4±11.4 years, mean preoperative body mass index (BMI) was 48.8±6.6 kg/m2, percent excess BMI lost (%EBL) was 62.6 ± 21.6%, mean weight change from nadir weight was 8.2±8.6 kg, and mean follow-up time was 40.5±26.7 months. Twelve patients had diabetes preoperatively.
RESULTS: Thirty-two of 36 patients (89%) had abnormal GTT. Six patients (17%) were identified as diabetic based on GTT. All six of these patients were diabetic preoperatively. Twenty-six patients (72%) had evidence of reactive hypoglycemia at 2 h post glucose load. Within this cohort of 26 patients, 14 had maximum to minimum glucose ratio (MMGR)>3:1, 5 with a ratio>4:1. Eleven patients had weight regain greater than 10% of initial weight loss (range 4.9-25.6 kg). Ten of these 11 patients (91%) with weight recidivism showed reactive hypoglycemia.
CONCLUSIONS: Abnormal GTT is a common finding post RYGB. Persistence of diabetes was noted in 50% of patients with diabetes preoperatively. Amongst the nondiabetic patients, reactive hypoglycemia was found to be more common and pronounced than expected. Absence of abnormally high insulin levels does not support nesidioblastosis as an etiology of this hypoglycemia. More than 50% of patients with reactive hypoglycemia had significantly exaggerated MMGR. We believe this may be due to the nonphysiologic transit of food to the small intestine due to lack of a pyloric valve after RYGB. This reactive hypoglycemia may contribute to maladaptive eating behaviors leading to weight regain long term. Our data suggest that GTT is an important part of post-RYGB follow-up and should be incorporated into the routine postoperative screening protocol. Further studies on the impact of pylorus preservation are necessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184112     DOI: 10.1007/s00464-010-1489-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  33 in total

1.  Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years.

Authors:  Nicolas V Christou; Didier Look; Lloyd D Maclean
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

2.  Remedial surgery following failed gastroplasty for morbid obesity.

Authors:  F E Eckhauser; J A Knol; W E Strodel
Journal:  Ann Surg       Date:  1983-11       Impact factor: 12.969

3.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 4.  Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.

Authors:  James F List; Joel F Habener
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-06       Impact factor: 4.310

5.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

Authors:  Loredana Farilla; Angela Bulotta; Boaz Hirshberg; Sergio Li Calzi; Nasif Khoury; Houtan Noushmehr; Cristina Bertolotto; Umberto Di Mario; David M Harlan; Riccardo Perfetti
Journal:  Endocrinology       Date:  2003-08-28       Impact factor: 4.736

6.  Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion.

Authors:  Manish Parikh; Patricia Ayoung-Chee; Eleny Romanos; Nichole Lewis; H Leon Pachter; George Fielding; Christine Ren
Journal:  J Am Coll Surg       Date:  2007-09-18       Impact factor: 6.113

7.  A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters.

Authors:  H J Sugerman; J V Starkey; R Birkenhauer
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

8.  Hyperinsulinemic hypoglycemia developing late after gastric bypass.

Authors:  John P Bantle; Sayeed Ikramuddin; Todd A Kellogg; Henry Buchwald
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

9.  The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion.

Authors:  W J Pories; E G Flickinger; D Meelheim; A M Van Rij; F T Thomas
Journal:  Ann Surg       Date:  1982-10       Impact factor: 12.969

10.  Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery.

Authors:  Glauco C Alvarez; Everton N Faria; Maristela Beck; Dener T Girardon; Ana Cristina Machado
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

View more
  22 in total

Review 1.  Weight recidivism post-bariatric surgery: a systematic review.

Authors:  Shahzeer Karmali; Balpreet Brar; Xinzhe Shi; Arya M Sharma; Christopher de Gara; Daniel W Birch
Journal:  Obes Surg       Date:  2013-11       Impact factor: 4.129

2.  Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures.

Authors:  Johanna Maria Brix; Hans-Peter Kopp; Florian Höllerl; Gerit Holger Schernthaner; Bernhard Ludvik; Guntram Schernthaner
Journal:  Obes Facts       Date:  2019-06-24       Impact factor: 3.942

Review 3.  Hyperinsulinemic hypoglycemia after gastric bypass surgery: what's up and what's down?

Authors:  A Yaqub; E P Smith; M Salehi
Journal:  Int J Obes (Lond)       Date:  2017-10-13       Impact factor: 5.095

4.  Laparoscopic reversal of Roux-en-Y gastric bypass: technique and utility for treatment of endocrine complications.

Authors:  Guilherme M Campos; Martynas Ziemelis; Rodis Paparodis; Muhammed Ahmed; Dawn Belt Davis
Journal:  Surg Obes Relat Dis       Date:  2013-06-29       Impact factor: 4.734

5.  Total pancreatectomy for the management of refractory post-gastric bypass hypoglycemia.

Authors:  Gaya Spolverato; Feriyl Bhaijee; Robert Anders; Kelsey Salley; Joan Parambi; Todd Brown; Timothy M Pawlik
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

Review 6.  Factors associated with weight regain post-bariatric surgery: a systematic review.

Authors:  Dimitrios I Athanasiadis; Anna Martin; Panagiotis Kapsampelis; Sara Monfared; Dimitrios Stefanidis
Journal:  Surg Endosc       Date:  2021-03-01       Impact factor: 4.584

Review 7.  Weight regain after gastric bypass: etiology and treatment options.

Authors:  Almantas Maleckas; Rita Gudaitytė; Rūta Petereit; Linas Venclauskas; Džilda Veličkienė
Journal:  Gland Surg       Date:  2016-12

8.  HFD refeeding in mice after fasting impairs learning by activating caspase-1 in the brain.

Authors:  Albert E Towers; Maci L Oelschlager; Michal B Juda; Sparsh Jain; Stephen J Gainey; Gregory G Freund
Journal:  Metabolism       Date:  2019-11-05       Impact factor: 8.694

9.  Impact of Carbohydrate Content and Glycemic Load on Postprandial Glucose After Roux-en-Y Gastric Bypass.

Authors:  Blandine Tramunt; Charlotte Vaurs; Jocelyne Lijeron; Eric Guillaume; Patrick Ritz; Chloé Diméglio; Hélène Hanaire
Journal:  Obes Surg       Date:  2016-07       Impact factor: 4.129

10.  Heterogeneity of proliferative markers in pancreatic β-cells of patients with severe hypoglycemia following Roux-en-Y gastric bypass.

Authors:  Mary-Elizabeth Patti; Allison B Goldfine; Jiang Hu; Dag Hoem; Anders Molven; Jeffrey Goldsmith; Wayne H Schwesinger; Stefano La Rosa; Franco Folli; Rohit N Kulkarni
Journal:  Acta Diabetol       Date:  2017-05-17       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.